Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Champions Oncology Inc. (CSBR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 14,627 | $79,132 | +34% | 0% |
| 2. | 9,700 | $52,477 | +111% | 0% | |
| 3. | 700 | $3,787 | -42% | 0% | |
| 4. | Renaissance Technologies Jim Simons | 124,791 | $701,000 | -1% | 0% |
| 5. | Millennium Management Israel Englander | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | Director | 198,625 | 2024-01-12 | Filing | |
| $6.27 | 2,000 | Director | 197,625 | 2024-01-11 | Filing | |
| $6.31 | 2,944 | Director | 195,625 | 2024-01-10 | Filing | |
| $6.25 | 3,000 | Director | 192,681 | 2024-01-09 | Filing | |
| $6.15 | 1,000 | Director | 189,681 | 2024-01-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.35 | 31,443 | Director | 0 | 2020-12-16 | Filing | |
| $5.25 | 75 | Officer, Director | 837,168 | 2020-03-24 | Filing | |
| $6.99 | 708,155 | Large Shareholder | 1,713,720 | 2020-03-06 | Filing | |
| $13.75 | 5,000 | Director | 57,500 | 2018-11-06 | Filing | |
| $13.02 | 8,333 | Director | 62,500 | 2018-09-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,421,673 | $13,609,560 | 2.43% | |
| 2. | 1,713,720 | $9,630,935 | 0.64% | |
| 3. | 684,578 | $3,847,260 | 0.06% | |
| 4. | 116,097 | $652,454 | 0% | |
| 5. | 82,837 | $465,535 | 0% |
News See All
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Champions Oncology's Fourth Quarter and Fiscal Year-End 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Champions Oncology Third Quarter Fiscal Year 2023 Earnings Call. It is now my pleasure to turn the floor over to your host, Dr.
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call.
How Champions Oncology Inc (CSBR) Stacks Up Against Its Peers
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
Champions Oncology Inc (CSBR) Stock: Have We Met?
This article has been removed due to violation of our Terms of Service.
Insider Selling at Domino's Pizza Inc. (DPZ) and Intel Corporation (INTC), Plus Insider Buying at Three Other Companies
Slightly more than a decade ago, the U.S. Congress enacted the Sarbanes-Oxley Act of 2002 that mandated significant changes to reporting requirements.
Notable Insider Selling at Applied Materials Inc. (AMAT) and Costco Wholesale (COST), Plus Insider Moves at 3 Other Companies
Although plenty of research concludes that securities purchases on the part of insiders tend to beat broader market benchmarks by a significant margin, Insider Monkey does not recommend that investors...